Expression of the major rheumatoid factor cross-reactive idiotype in pediatric patients with systemic lupus erythematosus

Vincent R. Bonagura, Norman Todd Ilowite, Lynda Hatam, David J. Valacer, Josiah F. Wedgwood

Research output: Contribution to journalArticle

4 Citations (Scopus)

Abstract

Rheumatoid factor cross-reactive idiotype (RF-CRI) is expressed in high concentrations in the sera of some patients with rheumatoid arthritis (RA) and juvenile rheumatoid arthritis (JRA). To determine if RF-CRI is specifically expressed in rheumatic disease or if it is secondary to polyclonal B-cell activation, we examined sera of 23 children with SLE, 16 adolescents with infectious mononucleosis (IM), and age-matched pediatric controls for RF-CRI expression. Concentrations of RF-CRI in serum, determined by an inhibition ELISA, were 24 ± 17 μg/ml (mean ± SD) in 25 normal children, 31 ± 17 in 16 young adults with IM, and were significantly increased, 70 ± 80 μg/ml, in the 23 children with SLE (p < 0.036). Eleven of 23 SLE patients had serum RF-CRI greater than the mean ± 2 SD for normal children. Ten of 23 SLE sera contained IgM rheumatoid factor (RF) activity. One patient with IM had a borderline elevated RF-CRI level, and 5 IM patients had RF in their sera. The serum IgM concentrations in sera were: SLE (192 ± 93 mg/dl) and IM (234 ± 77 mg/dl) sera. These levels were significantly elevated compared to controls (132 ± 44 mg/dl), p < 0.031 for SLE and p < 0.001 for IM, suggesting that polyclonal activation of B cells was present in SLE and IM patient groups. Increased expression of RF-CRI in the SLE patients correlated directly with high titer anti-DNA antibody values (r = 0.3965, p < 0.05) and RF activity when human IgG (r = 0.5026, p < 0.05) was used as the RF binding substrate and inversely with serum C3 levels (r = 0.3925, p < 0.05). RF-CRI expression did not correlate with RF that bound rabbit (r = 0.3123, p < 0.05). Increased serum RF-CRI expression is not a result of polyclonal B-cell activation. RF-CRI may be selectively up-regulated in patients with SLE.

Original languageEnglish (US)
Pages (from-to)232-243
Number of pages12
JournalClinical Immunology and Immunopathology
Volume60
Issue number2
DOIs
StatePublished - 1991
Externally publishedYes

Fingerprint

Rheumatoid Factor
Systemic Lupus Erythematosus
Pediatrics
Infectious Mononucleosis
Serum
B-Lymphocytes
Immunoglobulin M
Juvenile Arthritis
Antinuclear Antibodies
Rheumatic Diseases
Human Activities

ASJC Scopus subject areas

  • Immunology
  • Immunology and Allergy
  • Pathology and Forensic Medicine

Cite this

Expression of the major rheumatoid factor cross-reactive idiotype in pediatric patients with systemic lupus erythematosus. / Bonagura, Vincent R.; Ilowite, Norman Todd; Hatam, Lynda; Valacer, David J.; Wedgwood, Josiah F.

In: Clinical Immunology and Immunopathology, Vol. 60, No. 2, 1991, p. 232-243.

Research output: Contribution to journalArticle

Bonagura, Vincent R. ; Ilowite, Norman Todd ; Hatam, Lynda ; Valacer, David J. ; Wedgwood, Josiah F. / Expression of the major rheumatoid factor cross-reactive idiotype in pediatric patients with systemic lupus erythematosus. In: Clinical Immunology and Immunopathology. 1991 ; Vol. 60, No. 2. pp. 232-243.
@article{5ef459ef9b7242b9999efa85d63a46c4,
title = "Expression of the major rheumatoid factor cross-reactive idiotype in pediatric patients with systemic lupus erythematosus",
abstract = "Rheumatoid factor cross-reactive idiotype (RF-CRI) is expressed in high concentrations in the sera of some patients with rheumatoid arthritis (RA) and juvenile rheumatoid arthritis (JRA). To determine if RF-CRI is specifically expressed in rheumatic disease or if it is secondary to polyclonal B-cell activation, we examined sera of 23 children with SLE, 16 adolescents with infectious mononucleosis (IM), and age-matched pediatric controls for RF-CRI expression. Concentrations of RF-CRI in serum, determined by an inhibition ELISA, were 24 ± 17 μg/ml (mean ± SD) in 25 normal children, 31 ± 17 in 16 young adults with IM, and were significantly increased, 70 ± 80 μg/ml, in the 23 children with SLE (p < 0.036). Eleven of 23 SLE patients had serum RF-CRI greater than the mean ± 2 SD for normal children. Ten of 23 SLE sera contained IgM rheumatoid factor (RF) activity. One patient with IM had a borderline elevated RF-CRI level, and 5 IM patients had RF in their sera. The serum IgM concentrations in sera were: SLE (192 ± 93 mg/dl) and IM (234 ± 77 mg/dl) sera. These levels were significantly elevated compared to controls (132 ± 44 mg/dl), p < 0.031 for SLE and p < 0.001 for IM, suggesting that polyclonal activation of B cells was present in SLE and IM patient groups. Increased expression of RF-CRI in the SLE patients correlated directly with high titer anti-DNA antibody values (r = 0.3965, p < 0.05) and RF activity when human IgG (r = 0.5026, p < 0.05) was used as the RF binding substrate and inversely with serum C3 levels (r = 0.3925, p < 0.05). RF-CRI expression did not correlate with RF that bound rabbit (r = 0.3123, p < 0.05). Increased serum RF-CRI expression is not a result of polyclonal B-cell activation. RF-CRI may be selectively up-regulated in patients with SLE.",
author = "Bonagura, {Vincent R.} and Ilowite, {Norman Todd} and Lynda Hatam and Valacer, {David J.} and Wedgwood, {Josiah F.}",
year = "1991",
doi = "10.1016/0090-1229(91)90066-J",
language = "English (US)",
volume = "60",
pages = "232--243",
journal = "Clinical Immunology",
issn = "1521-6616",
publisher = "Academic Press Inc.",
number = "2",

}

TY - JOUR

T1 - Expression of the major rheumatoid factor cross-reactive idiotype in pediatric patients with systemic lupus erythematosus

AU - Bonagura, Vincent R.

AU - Ilowite, Norman Todd

AU - Hatam, Lynda

AU - Valacer, David J.

AU - Wedgwood, Josiah F.

PY - 1991

Y1 - 1991

N2 - Rheumatoid factor cross-reactive idiotype (RF-CRI) is expressed in high concentrations in the sera of some patients with rheumatoid arthritis (RA) and juvenile rheumatoid arthritis (JRA). To determine if RF-CRI is specifically expressed in rheumatic disease or if it is secondary to polyclonal B-cell activation, we examined sera of 23 children with SLE, 16 adolescents with infectious mononucleosis (IM), and age-matched pediatric controls for RF-CRI expression. Concentrations of RF-CRI in serum, determined by an inhibition ELISA, were 24 ± 17 μg/ml (mean ± SD) in 25 normal children, 31 ± 17 in 16 young adults with IM, and were significantly increased, 70 ± 80 μg/ml, in the 23 children with SLE (p < 0.036). Eleven of 23 SLE patients had serum RF-CRI greater than the mean ± 2 SD for normal children. Ten of 23 SLE sera contained IgM rheumatoid factor (RF) activity. One patient with IM had a borderline elevated RF-CRI level, and 5 IM patients had RF in their sera. The serum IgM concentrations in sera were: SLE (192 ± 93 mg/dl) and IM (234 ± 77 mg/dl) sera. These levels were significantly elevated compared to controls (132 ± 44 mg/dl), p < 0.031 for SLE and p < 0.001 for IM, suggesting that polyclonal activation of B cells was present in SLE and IM patient groups. Increased expression of RF-CRI in the SLE patients correlated directly with high titer anti-DNA antibody values (r = 0.3965, p < 0.05) and RF activity when human IgG (r = 0.5026, p < 0.05) was used as the RF binding substrate and inversely with serum C3 levels (r = 0.3925, p < 0.05). RF-CRI expression did not correlate with RF that bound rabbit (r = 0.3123, p < 0.05). Increased serum RF-CRI expression is not a result of polyclonal B-cell activation. RF-CRI may be selectively up-regulated in patients with SLE.

AB - Rheumatoid factor cross-reactive idiotype (RF-CRI) is expressed in high concentrations in the sera of some patients with rheumatoid arthritis (RA) and juvenile rheumatoid arthritis (JRA). To determine if RF-CRI is specifically expressed in rheumatic disease or if it is secondary to polyclonal B-cell activation, we examined sera of 23 children with SLE, 16 adolescents with infectious mononucleosis (IM), and age-matched pediatric controls for RF-CRI expression. Concentrations of RF-CRI in serum, determined by an inhibition ELISA, were 24 ± 17 μg/ml (mean ± SD) in 25 normal children, 31 ± 17 in 16 young adults with IM, and were significantly increased, 70 ± 80 μg/ml, in the 23 children with SLE (p < 0.036). Eleven of 23 SLE patients had serum RF-CRI greater than the mean ± 2 SD for normal children. Ten of 23 SLE sera contained IgM rheumatoid factor (RF) activity. One patient with IM had a borderline elevated RF-CRI level, and 5 IM patients had RF in their sera. The serum IgM concentrations in sera were: SLE (192 ± 93 mg/dl) and IM (234 ± 77 mg/dl) sera. These levels were significantly elevated compared to controls (132 ± 44 mg/dl), p < 0.031 for SLE and p < 0.001 for IM, suggesting that polyclonal activation of B cells was present in SLE and IM patient groups. Increased expression of RF-CRI in the SLE patients correlated directly with high titer anti-DNA antibody values (r = 0.3965, p < 0.05) and RF activity when human IgG (r = 0.5026, p < 0.05) was used as the RF binding substrate and inversely with serum C3 levels (r = 0.3925, p < 0.05). RF-CRI expression did not correlate with RF that bound rabbit (r = 0.3123, p < 0.05). Increased serum RF-CRI expression is not a result of polyclonal B-cell activation. RF-CRI may be selectively up-regulated in patients with SLE.

UR - http://www.scopus.com/inward/record.url?scp=0025858319&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0025858319&partnerID=8YFLogxK

U2 - 10.1016/0090-1229(91)90066-J

DO - 10.1016/0090-1229(91)90066-J

M3 - Article

C2 - 2070569

AN - SCOPUS:0025858319

VL - 60

SP - 232

EP - 243

JO - Clinical Immunology

JF - Clinical Immunology

SN - 1521-6616

IS - 2

ER -